In 2023, the first CRISPR–(Cas9)-based product was approved by the US Food and Drug Administration (FDA): Vertex/CRISPR Therapeutics’ Casgevy (exagamglogene autotemcel) for sickle cell disease (SCD) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results